Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenezumab OLE in Alzheimer's Disease
NCT03491150Phase 3Terminated
- Sponsor
- Roche
- Start
- Apr 2018
- Primary completion
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 3, open-label trial of crenezumab in Alzheimer's disease (AD) (2 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) at 54 weeks and Percentage of Participants With Anti-Crenezumab Antibodies at 54 weeks. Started Apr 2018; status: terminated.
02
Drugs
crenezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03491150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03491150.